Prostate Cell News Volume 7.03 | Jan 29 2016

Inhibition of FOXC2 Restores Epithelial Phenotype and Drug Sensitivity in Prostate Cancer Cells with Stem-Cell Properties
Investigators identified a critical nexus between p38MAPK signaling, and the transcription factor Forkhead Box Protein C2 (FOXC2) known to promote cancer stem-cells and metastasis. [Oncogene] Full Article

Inhibition of Lysyl Oxidase and Lysyl Oxidase-Like Enzymes Has Tumor-Promoting and Tumor-Suppressing Roles in Experimental Prostate Cancer
Researchers showed that orthotopic implantation of rat prostate AT-1 tumor cells increased lysyl oxidase (LOX) and LOX-like microRNA expressions in the tumor and in the surrounding non-malignant prostate tissue. [Sci Rep] Full Article

Phenethyl Isothiocyanate (PEITC) Suppresses Prostate Cancer Cell Invasion Epigenetically through Regulating MicroRNA-194
Altered levels of microRNA (miRNA) have been linked to tumor malignancy due to their capacity to regulate functional gene expression in carcinogenesis. Scientist assessed the effects of PEITC on miRNA expression which is related to prostate cancer cell invasiveness. [Mol Nutr Food Res] Abstract

Increase in Prostate Stem Cell Antigen Expression in Prostatic Hyperplasia Induced by Testosterone and 17β-Estradiol in C57BL Mice
To understand the mechanisms underlying the hormonal induction of prostatic hyperplasia, the authors investigated the expression of growth factors and their receptors, androgen receptor, estrogen receptor, and prostatic secretory proteins. [J Steroid Biochem Mol Biol] Abstract

3D Cell-SELEX: Development of RNA Aptamers as Molecular Probes for PC-3 Tumor Cell Line
Scientists performed three-dimensional Cell-SELEX against PC-3 prostate cancer cell line, a novel strategy to select specific nucleic acid ligands against spheroid cells in three-dimensional cell culture. [Exp Cell Res] Abstract

Oncolytic Vaccinia Virus as a Vector for Therapeutic Sodium Iodide Symporter Gene Therapy in Prostate Cancer
Scientist evaluated the therapeutic potential of vaccinia virus expressing the sodium iodide symporter (NIS) in prostate cancer models, combining oncolysis, external beam radiotherapy, and NIS-mediated radioiodide therapy. [Gene Ther] Full Article

CLINICAL RESEARCH

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
A total of 396 men with nonmetastatic or metastatic castration-resistant prostate cancer were randomly assigned to enzalutamide 160 mg per day or bicalutamide 50 mg per day. Androgen deprivation therapy was continued in both arms. The primary end point was progression-free survival. [J Clin Oncol] Full Article

5-Alpha Reductase Inhibitor Use and Prostate Cancer Survival in the Finnish Prostate Cancer Screening Trial
The authors studied disease-specific survival by 5α-reductase inhibitors usage in a cohort of 6,537 prostate cancer cases diagnosed in the Finnish Prostate Cancer Screening Trial and linked to the national prescription database for information on medication use. [Int J Cancer] Abstract

The Prognostic Role of Preoperative Serum C-Reactive Protein in Predicting the Biochemical Recurrence in Patients Treated with Radical Prostatectomy
Preoperative C-reactive protein (CRP) is elevated in patients with pathological features of aggressive prostate cancer and biochemical recurrence after radical prostatectomy. While CRP has independent prognostic value, it does not add prognostically or clinically significant information to standard predictors of outcomes. [Prostate Cancer Prostatic Dis] Abstract

Prospects for the Use of Ipilimumab in Treating Advanced Prostate Cancer
Results of key clinical studies of ipilimumab in the treatment of prostate cancer, including clinical efficacy and toxicities, are summarized. [Expert Opin Biol Ther] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

FDA Approves Eisai’s Halaven^® (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Eisai Inc. announced that the United States Food and Drug Administration (FDA) approved Halaven^® (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [Eisai Inc.] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM. Watch the webinar.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Post-Doc Fellowship – Molecular Imaging for Prostate Cancer (Case Western Reserve University)

Post-Doc Fellowship/Staff Scientist – Prostate Cancer Epidemiology (Memorial Sloan Kettering Cancer Center)

Postdoctoral Researcher – Prostate Cancer Biology (Roswell Park Cancer Institute)

Faculty Position – Urology Research (Mayo Clinic)

Faculty Position – Cancer Biology (Michigan State University)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Position – Bioinformatics (Princess Margaret Cancer Centre)

Professor Position – Cancer Immunotherapy (City of Hope)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.